<DOC>
	<DOCNO>NCT01472510</DOCNO>
	<brief_summary>This study design confirm investigational drug Ranibizumab give injection eye safe effective use people diabetic macular edema ( DME ) .</brief_summary>
	<brief_title>Ranibizumab Residual Diabetic Macular Edema Following Previous Anti-VEGF Therapy</brief_title>
	<detailed_description>Ranibizumab work block Vascular Endothelial Growth Factor ( VEGF ) , substance find eye diabetic eye disease cause leakage blood vessel . Several study suggest eye DME may high level VEGF ; therefore , Ranibizumab may helpful block VEGF decrease DME . Ranibizumab approve U.S. Food Drug Administration ( FDA ) treatment wet age-related macular degeneration ( AMD ) Retinal Vein Occlusion dose amount 0.5 mg. Ranibizumab approve use subject DME .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Subjects eligible follow criterion meet : 1 . Age &gt; 18 year 2 . Diagnosis diabetes mellitus ( type 1 2 ) 3 . Residual edema determine mean foveal thickness Cirrus OCT &gt; 300 micron leakage see FA baseline 4 . Clinical evidence retinal thickening due macular edema involve center macula , associate diabetic retinopathy . 5 . Previous history least 4 consecutive antiVEGF intravitreal injection Pegaptanib sodium Bevacizumab ( consecutive injection administer 6 week apart last year ) treatment diabetic macular edema . 6 . Previous history focal laser and/or intravitreal steroid injection treatment diabetic macular edema . 7 . BCVA 20/3220/400 ( ETDRS ) 8 . Media clarity , pupillary dilation patient cooperation sufficient allow OCT test retinal photography 1 . Pregnancy ( positive pregnancy test ) know pregnant ; also premenopausal woman use adequate contraception . . The following consider effective mean contraception : surgical sterilization use oral contraceptive , barrier contraception either condom diaphragm conjunction spermicidal gel , IUD , contraceptive hormone implant patch . 2 . Participation another ocular investigation trial simultaneously . 3 . Systemic use antiVEGF within 3 month prior day 0 . 4 . Previous intravitreal ranibizumab within 3 month prior day 0 5 . Blood pressure &gt; 180/110 ( systolic 180 OR diastolic 110 ) 6 . Any condition , opinion investigator , would preclude participation study ( e.g . chronic alcoholism , drug abuse ) . 7 . Evidence vitreoretinal interface abnormality ocular exam OCT may contribute macular edema . 8 . An eye , investigator 's opinion , chance improve visual acuity follow resolution macular edema ( e.g . presence subretinal fibrosis , ischemic maculopathy geographic atrophy ) . 9 . Presence another ocular condition may affect visual acuity macular edema course study ( e.g . AMD , uveitis , IrvineGass ) . 10 . Evidence active neovascularization iris retina . 11 . Evidence central atrophy fibrosis study eye . 12 . Presence substantial cataract , one might decrease vision 3 line vision sometime study . 13 . History vitreous surgery study eye . 14 . History cataract surgery within 6 month enrollment . 15 . History YAG capsulotomy within 2 month enrollment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Diabetic</keyword>
	<keyword>Macular</keyword>
	<keyword>Edema</keyword>
	<keyword>Ranibizumab</keyword>
	<keyword>anti-VEGF</keyword>
</DOC>